The impact of modulating the gastrointestinal microbiota in cancer patients

Gastrointestinal microbiota is vastly deregulated in cancer patients due to different factors, but the exact mechanisms of interaction between cancer and microbiome are still poorly understood. Current evidence suggests that alterations in the composition of the microbiota may affect efficacy and to...

Full description

Saved in:
Bibliographic Details
Published in:Baillière's best practice & research. Clinical gastroenterology 2020-10, Vol.48-49, p.101700-101700, Article 101700
Main Authors: Morkūnas, Egidijus, Skiecevičienė, Jurgita, Kupčinskas, Juozas
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacteria
Cancer
Cancer therapies
Checkpoint inhibitors
Chemotherapy
Cytotoxicity
Diarrhea
Disease Models, Animal
Faecal microbiome transplantation
Fecal Microbiota Transplantation - methods
Gastrointestinal Microbiome - physiology
Gram-positive bacteria
Hematology
Humans
Immunotherapy
Immunotherapy - methods
Kinases
Melanoma
Metastasis
Microbiome modulation
Microbiota
Mucositis
Neoplasms - microbiology
Neoplasms - therapy
Pathogenesis
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal microbiota is vastly deregulated in cancer patients due to different factors, but the exact mechanisms of interaction between cancer and microbiome are still poorly understood. Current evidence suggests that alterations in the composition of the microbiota may affect efficacy and toxicity of anti-cancer therapies. Recent preclinical and clinical studies demonstrate different mechanisms and outcomes of deregulation of gut microbiome, and investigate effects of modulating gastrointestinal microbiota in cancer patients. This paper reviews effects of altered microbiome on anti-cancer management, including antibiotics, chemotherapy and immunotherapy, as well as possible outcomes of modulating altered microbiome by probiotics or faecal microbiome transplantation in cancer patients.
ISSN:1521-6918
1532-1916
DOI:10.1016/j.bpg.2020.101700